Dr. Andrew Huberman

And psilocybin appears to bind near selectively to a particular serotonin receptor, and the outcome seems to be enhanced or more broad connectivity between brain areas that normally are not communicating with one another.

Probably not the growth of new connections, but the, let's say, the unveiling of the ability for communication

certain brain areas to communicate with one another, whereas they couldn't prior.

Different ways of thinking about the same problems, which is...

logically sound if you think about ways to deal with depression.

Depression is characterized by a number of things, of course, but one of the hallmark features of depression, in addition to sleep challenges, is a lack of positive anticipation of the future.

And it does seem that these macrodose psilocybin trials are helpful for that.

Turns out that the microdosing of psilocybin has not been shown to be terribly effective, which is not to say

It isn't, but the trials don't support that, although there aren't many trials of that yet.

So it appears, you know, if you had to pick between micro and macro dosing, go macro.

But be careful.

Be careful, and set and setting is important.

Safety is important, and certainly not for children.

And as long as we're adolescents or teenagers, I really, again, want to reemphasize that.

The other thing is as long as we're talking about psychedelics and hallucinogens, we should probably just touch on MDMA for a moment.

First of all, MDMA ecstasy has a number of challenges or potential problems that need to be highlighted.

First of all,

contaminants, you know, we have a fentanyl crisis in the U.S., so contaminants, so purity is essential.

Second of all, it is methylene dioxide methamphetamine.

And the methamphetamine part often gets people thinking like, whoa.